ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Serum Soluble Asialoglycoprotein Receptor 1: A Potential Predictor Marker Linked to Type 2 Diabetes Mellitus, Demonstrating Positive Correlation With High Sensitive C-Reactive Protein.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Proteome-wide genetic analyses identify ASGR1 as a potential biomarker linking smoking with ischemic heart disease.Nature cardiovascular research · 2026Article
- Epigenetic Mechanisms Linking Chronic Obstructive Pulmonary Disease and Atrial Fibrillation: A Multi-Omics Mendelian Randomization Study.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asialoglycoprotein receptor 1 (ASGR1) deficiency has been implicated in enhancing liver insulin sensitivity and reducing systemic insulin resistance, thus highlighting its pivotal role in glucose metabolism. However, the association between serum soluble asialoglycoprotein receptor 1 (sASGR1) and type 2 diabetes mellitus (T2DM) remains elusive. Therefore, we conducted a study to delve into this association. Methods: From July to October 2024, 220 newly diagnosed T2DM patients and an equal number of matched controls with normal glucose tolerance (NGT) were enrolled. Serum sASGR1 levels were quantified using ELISA, and the carotid artery and liver were assessed with ultrasound imaging. Results: The median serum sASGR1 level was significantly higher in the T2DM group (6.58 ng/mL) compared to the NGT group (5.26 ng/mL). Notably, no significant difference in sASGR1 levels was observed between individuals with and without carotid atherosclerosis or fatty liver. In the NGT group, sASGR1 levels exhibited a positive correlation with high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6). Among T2DM patients, sASGR1 levels were positively associated with estimated glomerular filtration rate (eGFR), insulin resistance (as measured by HOMA-IR), triglycerides (TG), and hs-CRP, but negatively associated with creatinine (Cr). The linear regression analysis identified Cr as an independent negative factor and hs-CRP as an independent positive factor of serum sASGR1 levels. Logistic regression analysis indicated that the highest sASGR1 group had significantly higher odds of developing T2DM compared to the lowest group, even after adjusting for potential confounders. However, this significance was attenuated after further adjustment for hs-CRP. The area under the receiver operating characteristic (ROC) curve for sASGR1 was 0.610. Conclusion: Serum sASGR1 levels are elevated in newly diagnosed T2DM patients and correlate positively with hs-CRP. However, sASGR1 demonstrates limited predictive value for the onset of T2DM. Further research is warranted to explore the potential role of sASGR1 in renal function, blood lipids, liver health, and arteriosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.